AU6219400A - The il-1l1 gene and polypeptide products - Google Patents

The il-1l1 gene and polypeptide products Download PDF

Info

Publication number: AU6219400A
Authority: AU; Australia
Prior art keywords: gene; nucleic acid; seq; polypeptide; protein
Prior art date: 1999-07-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU62194/00A

Other languages

English (en)

Inventor

Jenny Barton

Martin Nicklin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Interleukin Genetics Inc

Original Assignee

Interleukin Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-16

Filing date

2000-07-17

Publication date

2001-02-05

2000-07-17 Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc

2001-02-05 Publication of AU6219400A publication Critical patent/AU6219400A/en

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims description 574
108090000765 processed proteins & peptides Proteins 0.000 title claims description 296
102000004196 processed proteins & peptides Human genes 0.000 title claims description 263
229920001184 polypeptide Polymers 0.000 title claims description 246
150000007523 nucleic acids Chemical class 0.000 claims description 221
102000039446 nucleic acids Human genes 0.000 claims description 184
108020004707 nucleic acids Proteins 0.000 claims description 184
125000003729 nucleotide group Chemical group 0.000 claims description 139
239000002773 nucleotide Substances 0.000 claims description 136
241000282414 Homo sapiens Species 0.000 claims description 98
230000000295 complement effect Effects 0.000 claims description 57
108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
150000001413 amino acids Chemical class 0.000 claims description 40
125000003275 alpha amino acid group Chemical group 0.000 claims description 39
239000013598 vector Substances 0.000 claims description 31
241000124008 Mammalia Species 0.000 claims description 15
230000004927 fusion Effects 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 description 257
235000018102 proteins Nutrition 0.000 description 234
210000004027 cell Anatomy 0.000 description 189
238000000034 method Methods 0.000 description 163
230000014509 gene expression Effects 0.000 description 125
101710089409 Interleukin-36 receptor antagonist protein Proteins 0.000 description 118
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 101
102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 93
108010002352 Interleukin-1 Proteins 0.000 description 86
241001465754 Metazoa Species 0.000 description 85
230000000694 effects Effects 0.000 description 84
102000000589 Interleukin-1 Human genes 0.000 description 82
201000010099 disease Diseases 0.000 description 81
102000053602 DNA Human genes 0.000 description 80
108020004414 DNA Proteins 0.000 description 80
108700028369 Alleles Proteins 0.000 description 78
230000027455 binding Effects 0.000 description 72
150000001875 compounds Chemical class 0.000 description 72
239000012634 fragment Substances 0.000 description 63
102000005962 receptors Human genes 0.000 description 63
108020003175 receptors Proteins 0.000 description 63
108700019146 Transgenes Proteins 0.000 description 61
239000000523 sample Substances 0.000 description 58
230000009261 transgenic effect Effects 0.000 description 56
108091034117 Oligonucleotide Proteins 0.000 description 54
230000035772 mutation Effects 0.000 description 49
239000005557 antagonist Substances 0.000 description 47
108020004999 messenger RNA Proteins 0.000 description 46
238000012360 testing method Methods 0.000 description 45
210000001519 tissue Anatomy 0.000 description 45
239000000556 agonist Substances 0.000 description 43
230000000692 anti-sense effect Effects 0.000 description 41
238000003556 assay Methods 0.000 description 41
239000013615 primer Substances 0.000 description 41
239000003550 marker Substances 0.000 description 38
235000001014 amino acid Nutrition 0.000 description 36
229940024606 amino acid Drugs 0.000 description 35
239000003814 drug Substances 0.000 description 33
239000000047 product Substances 0.000 description 33
230000003993 interaction Effects 0.000 description 31
239000002299 complementary DNA Substances 0.000 description 30
229920002477 rna polymer Polymers 0.000 description 30
238000001514 detection method Methods 0.000 description 29
230000006870 function Effects 0.000 description 29
230000002068 genetic effect Effects 0.000 description 29
238000004458 analytical method Methods 0.000 description 28
102000004190 Enzymes Human genes 0.000 description 25
108090000790 Enzymes Proteins 0.000 description 25
230000004075 alteration Effects 0.000 description 25
229940088598 enzyme Drugs 0.000 description 25
102000037865 fusion proteins Human genes 0.000 description 25
108020001507 fusion proteins Proteins 0.000 description 25
238000003752 polymerase chain reaction Methods 0.000 description 25
230000001105 regulatory effect Effects 0.000 description 25
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 24
229940079593 drug Drugs 0.000 description 24
210000001161 mammalian embryo Anatomy 0.000 description 24
108091026890 Coding region Proteins 0.000 description 23
102000053642 Catalytic RNA Human genes 0.000 description 22
108090000994 Catalytic RNA Proteins 0.000 description 22
241001529936 Murinae Species 0.000 description 22
238000009396 hybridization Methods 0.000 description 22
108091092562 ribozyme Proteins 0.000 description 22
238000003199 nucleic acid amplification method Methods 0.000 description 21
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 20
230000003321 amplification Effects 0.000 description 20
230000004071 biological effect Effects 0.000 description 20
208000035475 disorder Diseases 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 19
239000013604 expression vector Substances 0.000 description 19
230000004913 activation Effects 0.000 description 18
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 17
108010091086 Recombinases Proteins 0.000 description 17
-1 cholesterol) Chemical class 0.000 description 17
230000018109 developmental process Effects 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
238000012216 screening Methods 0.000 description 17
230000002103 transcriptional effect Effects 0.000 description 17
241000699666 Mus <mouse, genus> Species 0.000 description 16
102000018120 Recombinases Human genes 0.000 description 16
230000001594 aberrant effect Effects 0.000 description 16
230000000875 corresponding effect Effects 0.000 description 16
238000012217 deletion Methods 0.000 description 16
230000037430 deletion Effects 0.000 description 16
230000001419 dependent effect Effects 0.000 description 16
238000011161 development Methods 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
230000014616 translation Effects 0.000 description 16
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 15
230000002757 inflammatory effect Effects 0.000 description 15
230000006798 recombination Effects 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
238000013519 translation Methods 0.000 description 15
230000001413 cellular effect Effects 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
230000008685 targeting Effects 0.000 description 14
108020005345 3' Untranslated Regions Proteins 0.000 description 13
238000003776 cleavage reaction Methods 0.000 description 13
230000002950 deficient Effects 0.000 description 13
241000894007 species Species 0.000 description 13
238000013518 transcription Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
108091060211 Expressed sequence tag Proteins 0.000 description 12
239000000203 mixture Substances 0.000 description 12
102000054765 polymorphisms of proteins Human genes 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
230000007017 scission Effects 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 11
108700026244 Open Reading Frames Proteins 0.000 description 11
230000003042 antagnostic effect Effects 0.000 description 11
239000000074 antisense oligonucleotide Substances 0.000 description 11
238000012230 antisense oligonucleotides Methods 0.000 description 11
230000008901 benefit Effects 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
210000000349 chromosome Anatomy 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
150000003384 small molecules Chemical group 0.000 description 11
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 10
108090000695 Cytokines Proteins 0.000 description 10
108050006617 Interleukin-1 receptor Proteins 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
238000013459 approach Methods 0.000 description 10
230000004077 genetic alteration Effects 0.000 description 10
231100000118 genetic alteration Toxicity 0.000 description 10
230000002163 immunogen Effects 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
229940044551 receptor antagonist Drugs 0.000 description 10
239000002464 receptor antagonist Substances 0.000 description 10
238000005215 recombination Methods 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
238000011282 treatment Methods 0.000 description 10
108020005544 Antisense RNA Proteins 0.000 description 9
102000019223 Interleukin-1 receptor Human genes 0.000 description 9
108020004511 Recombinant DNA Proteins 0.000 description 9
108700008625 Reporter Genes Proteins 0.000 description 9
239000002253 acid Substances 0.000 description 9
238000007792 addition Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
210000002257 embryonic structure Anatomy 0.000 description 9
230000009395 genetic defect Effects 0.000 description 9
210000004602 germ cell Anatomy 0.000 description 9
238000002744 homologous recombination Methods 0.000 description 9
230000006801 homologous recombination Effects 0.000 description 9
208000027866 inflammatory disease Diseases 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
239000003446 ligand Substances 0.000 description 9
230000037230 mobility Effects 0.000 description 9
210000002826 placenta Anatomy 0.000 description 9
108010051219 Cre recombinase Proteins 0.000 description 8
241000251539 Vertebrata <Metazoa> Species 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
239000000427 antigen Substances 0.000 description 8
230000000890 antigenic effect Effects 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
230000008859 change Effects 0.000 description 8
210000001671 embryonic stem cell Anatomy 0.000 description 8
238000003018 immunoassay Methods 0.000 description 8
238000002372 labelling Methods 0.000 description 8
210000004940 nucleus Anatomy 0.000 description 8
230000008569 process Effects 0.000 description 8
230000011664 signaling Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
240000004808 Saccharomyces cerevisiae Species 0.000 description 7
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
238000002105 Southern blotting Methods 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
238000010367 cloning Methods 0.000 description 7
239000003184 complementary RNA Substances 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
238000000520 microinjection Methods 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
239000002987 primer (paints) Substances 0.000 description 7
238000007423 screening assay Methods 0.000 description 7
238000012163 sequencing technique Methods 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
102000014914 Carrier Proteins Human genes 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 6
108060002716 Exonuclease Proteins 0.000 description 6
101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 6
108090001005 Interleukin-6 Proteins 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 6
239000011324 bead Substances 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
210000003527 eukaryotic cell Anatomy 0.000 description 6
102000013165 exonuclease Human genes 0.000 description 6
102000054766 genetic haplotypes Human genes 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000011065 in-situ storage Methods 0.000 description 6
230000028709 inflammatory response Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
230000002463 transducing effect Effects 0.000 description 6
238000001890 transfection Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108700024394 Exon Proteins 0.000 description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
101150034230 LI gene Proteins 0.000 description 5
101710181812 Methionine aminopeptidase Proteins 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
108010029485 Protein Isoforms Proteins 0.000 description 5
102000001708 Protein Isoforms Human genes 0.000 description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
108091036066 Three prime untranslated region Proteins 0.000 description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Chemical group 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
230000001270 agonistic effect Effects 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
230000000975 bioactive effect Effects 0.000 description 5
238000000423 cell based assay Methods 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
238000002742 combinatorial mutagenesis Methods 0.000 description 5
229940000406 drug candidate Drugs 0.000 description 5
108091008053 gene clusters Proteins 0.000 description 5
238000010353 genetic engineering Methods 0.000 description 5
208000019622 heart disease Diseases 0.000 description 5
210000003917 human chromosome Anatomy 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
230000004968 inflammatory condition Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
239000000816 peptidomimetic Substances 0.000 description 5
230000002974 pharmacogenomic effect Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
239000003270 steroid hormone Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000012546 transfer Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
206010009900 Colitis ulcerative Diseases 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
108010000912 Egg Proteins Proteins 0.000 description 4
102000002322 Egg Proteins Human genes 0.000 description 4
108091008794 FGF receptors Proteins 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
229920002971 Heparan sulfate Polymers 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
102100020881 Interleukin-1 alpha Human genes 0.000 description 4
102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 4
101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
201000006704 Ulcerative Colitis Diseases 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
208000004631 alopecia areata Diseases 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
210000001109 blastomere Anatomy 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000010354 integration Effects 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000003278 mimic effect Effects 0.000 description 4
210000004681 ovum Anatomy 0.000 description 4
230000004481 post-translational protein modification Effects 0.000 description 4
230000000770 proinflammatory effect Effects 0.000 description 4
210000001236 prokaryotic cell Anatomy 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000003757 reverse transcription PCR Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
230000009466 transformation Effects 0.000 description 4
208000019553 vascular disease Diseases 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
208000006332 Choriocarcinoma Diseases 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
206010059866 Drug resistance Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108091029865 Exogenous DNA Proteins 0.000 description 3
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
102000005720 Glutathione transferase Human genes 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
206010038997 Retroviral infections Diseases 0.000 description 3
108091081021 Sense strand Proteins 0.000 description 3
241000251131 Sphyrna Species 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
229940009098 aspartate Drugs 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
210000002459 blastocyst Anatomy 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
210000004413 cardiac myocyte Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
230000009918 complex formation Effects 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
108091036078 conserved sequence Proteins 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
230000004720 fertilization Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000010363 gene targeting Methods 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
230000012010 growth Effects 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
230000036543 hypotension Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
229940100601 interleukin-6 Drugs 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
238000011813 knockout mouse model Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000007834 ligase chain reaction Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000013011 mating Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
230000037361 pathway Effects 0.000 description 3
208000028169 periodontal disease Diseases 0.000 description 3
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
239000004474 valine Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
108020005065 3' Flanking Region Proteins 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
108020004491 Antisense DNA Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
102000052052 Casein Kinase II Human genes 0.000 description 2
108010010919 Casein Kinase II Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010046276 FLP recombinase Proteins 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
208000003807 Graves Disease Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
108091027305 Heteroduplex Proteins 0.000 description 2
101001040964 Homo sapiens Interleukin-36 receptor antagonist protein Proteins 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
102100039065 Interleukin-1 beta Human genes 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 2
101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 2
102000004557 Interleukin-18 Receptors Human genes 0.000 description 2
108010017537 Interleukin-18 Receptors Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
102000004195 Isomerases Human genes 0.000 description 2
108090000769 Isomerases Proteins 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
101150075239 L1 gene Proteins 0.000 description 2
108010014691 Lithostathine Proteins 0.000 description 2
102100027361 Lithostathine-1-alpha Human genes 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
241001045988 Neogene Species 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
102000016978 Orphan receptors Human genes 0.000 description 2
108070000031 Orphan receptors Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
241000009328 Perro Species 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
208000002787 Pregnancy Complications Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
230000010799 Receptor Interactions Effects 0.000 description 2
108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
206010043647 Thrombotic Stroke Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000003816 antisense DNA Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000004507 artificial chromosome Anatomy 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
229950004398 broxuridine Drugs 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
208000015606 cardiovascular system disease Diseases 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000008711 chromosomal rearrangement Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000004554 glutamine Nutrition 0.000 description 2
108010038082 heparin proteoglycan Proteins 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000003960 inflammatory cascade Effects 0.000 description 2
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
208000018773 low birth weight Diseases 0.000 description 2
231100000533 low birth weight Toxicity 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000008018 melting Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
230000033607 mismatch repair Effects 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
101150091879 neo gene Proteins 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
208000012113 pregnancy disease Diseases 0.000 description 2
230000002028 premature Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
108700015048 receptor decoy activity proteins Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000001626 skin fibroblast Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
108091006106 transcriptional activators Proteins 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
RFFPAVPLLZAQTB-JJYYJPOSSA-N (2s,3r,4r)-2,3,4,5-tetrahydroxypentanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(F)=O RFFPAVPLLZAQTB-JJYYJPOSSA-N 0.000 description 1
230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282985 Cervus Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
108020001738 DNA Glycosylase Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
102000028381 DNA glycosylase Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 1
101100084900 Drosophila melanogaster Rpn11 gene Proteins 0.000 description 1
108700039964 Duplicate Genes Proteins 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
244000148064 Enicostema verticillatum Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101710100588 Erythroid transcription factor Proteins 0.000 description 1
102100031690 Erythroid transcription factor Human genes 0.000 description 1
241000702191 Escherichia virus P1 Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
101710082961 GATA-binding factor 2 Proteins 0.000 description 1
241000197200 Gallinago media Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
241000696272 Gull adenovirus Species 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 1
101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000001284 I-kappa-B kinase Human genes 0.000 description 1
108060006678 I-kappa-B kinase Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000017182 Ikaros Transcription Factor Human genes 0.000 description 1
108010013958 Ikaros Transcription Factor Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
229940123871 Interleukin 1 agonist Drugs 0.000 description 1
229940124084 Interleukin 1 antagonist Drugs 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 description 1
101710138729 Interleukin-18 receptor accessory protein Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
101001040935 Mus musculus Interleukin-36 receptor antagonist protein Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033963 Parathyroid tumour Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
241000219061 Rheum Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000225041 Roestes Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
241000248384 Tetrahymena thermophila Species 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
102100027010 Toll-like receptor 1 Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000003314 affinity selection Methods 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
210000001776 amniocyte Anatomy 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000003322 aneuploid effect Effects 0.000 description 1
208000036878 aneuploidy Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
238000010420 art technique Methods 0.000 description 1
210000004618 arterial endothelial cell Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000004252 chorionic villi Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000004927 clay Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000006467 collateral growth Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
239000000430 cytokine receptor antagonist Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002458 fetal heart Anatomy 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
125000001965 gamma-lactamyl group Chemical group 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
201000010235 heart cancer Diseases 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000024348 heart neoplasm Diseases 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000003268 heterogeneous phase assay Methods 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000012966 insertion method Methods 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
230000007154 intracellular accumulation Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000000982 limb bud Anatomy 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000001459 lithography Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004939 midgestation embryo Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
101150029137 mutY gene Proteins 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
238000007857 nested PCR Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
238000011330 nucleic acid test Methods 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000003793 prenatal diagnosis Methods 0.000 description 1
238000009598 prenatal testing Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940070353 protamines Drugs 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000001853 pulsed-field electrophoresis Methods 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000020129 regulation of cell death Effects 0.000 description 1
230000009703 regulation of cell differentiation Effects 0.000 description 1
230000021014 regulation of cell growth Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
108091035233 repetitive DNA sequence Proteins 0.000 description 1
102000053632 repetitive DNA sequence Human genes 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
150000003515 testosterones Chemical class 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
208000017997 tumor of parathyroid gland Diseases 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
239000000277 virosome Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
101150061422 yip5 gene Proteins 0.000 description 1
210000004340 zona pellucida Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Hematology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)

AU62194/00A 1999-07-16 2000-07-17 The il-1l1 gene and polypeptide products Abandoned AU6219400A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14429899P	1999-07-16	1999-07-16
US60/144298		1999-07-16
PCT/US2000/019508 WO2001005974A2 (fr)	1999-07-16	2000-07-17	Gène il-1l1 et produits polypeptidiques

Publications (1)

Publication Number	Publication Date
AU6219400A true AU6219400A (en)	2001-02-05

Family

ID=22507973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU62194/00A Abandoned AU6219400A (en)	1999-07-16	2000-07-17	The il-1l1 gene and polypeptide products

Country Status (6)

Country	Link
EP (1)	EP1200593A2 (fr)
JP (1)	JP2003523943A (fr)
AU (1)	AU6219400A (fr)
CA (1)	CA2378954A1 (fr)
IL (1)	IL147534A0 (fr)
WO (1)	WO2001005974A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999035268A1 (fr)	1998-01-09	1999-07-15	Immunex Corporation	Adn codant il-1 delta et polypeptides il-1 delta
US20030100031A1 (en) *	2001-06-11	2003-05-29	Steven Dower	Integrative assays for monitoring molecular assembly events
EP1585482A4 (fr) *	2002-09-25	2009-09-09	Genentech Inc	Nouvelles compositions et methodes de traitement du psoriasis
US20100031378A1 (en)	2008-08-04	2010-02-04	Edwards Joel A	Novel gene disruptions, compositions and methods relating thereto
US20070178520A1 (en) *	2004-02-27	2007-08-02	Barbara Wolff-Winiski	Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
CA2662549C (fr) *	2006-09-08	2014-10-28	Amgen Inc.	Variants de la famille il-1
EP3554343A1 (fr) *	2016-12-14	2019-10-23	Progenity, Inc.	Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
CN107362351B (zh) *	2017-09-04	2020-11-10	上海市儿童医院	Il-36r的拮抗剂在制备镇痛药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0977779A1 (fr) *	1997-04-21	2000-02-09	Schering Corporation	Cytokines de mammifere; reactifs et procedes connexes
WO1999035268A1 (fr) *	1998-01-09	1999-07-15	Immunex Corporation	Adn codant il-1 delta et polypeptides il-1 delta
AU769262B2 (en) *	1998-04-03	2004-01-22	Arca Biopharma, Inc.	A interleukin-1 receptor antagonist and uses thereof
AU5772299A (en) *	1998-08-07	2000-02-28	Millennium Pharmaceuticals, Inc.	Novel molecules of the tango-93-related protein family and uses thereof
WO2000020595A1 (fr) *	1998-10-08	2000-04-13	Zymogenetics, Inc.	Homologues de l'interleukine-1
JP5456222B2 (ja) *	1998-12-23	2014-03-26	ジェネンテック，インコーポレイテッド	Ｉｌ−１関連ポリペプチド

2000
- 2000-07-17 CA CA002378954A patent/CA2378954A1/fr not_active Abandoned
- 2000-07-17 EP EP00948733A patent/EP1200593A2/fr not_active Withdrawn
- 2000-07-17 WO PCT/US2000/019508 patent/WO2001005974A2/fr not_active Application Discontinuation
- 2000-07-17 JP JP2001511187A patent/JP2003523943A/ja not_active Abandoned
- 2000-07-17 AU AU62194/00A patent/AU6219400A/en not_active Abandoned
- 2000-07-17 IL IL14753400A patent/IL147534A0/xx unknown

Also Published As

Publication number	Publication date
IL147534A0 (en)	2002-08-14
WO2001005974A3 (fr)	2001-05-10
WO2001005974A9 (fr)	2001-06-28
EP1200593A2 (fr)	2002-05-02
JP2003523943A (ja)	2003-08-12
WO2001005974A2 (fr)	2001-01-25
CA2378954A1 (fr)	2001-01-25

Publication	Publication Date	Title
US5800998A (en)	1998-09-01	Assays for diagnosing type II diabetes in a subject
US6031076A (en)	2000-02-29	Conservin compositions
US6143491A (en)	2000-11-07	Therapeutic compositions and methods and diagnostic assays for type II diabetes involving HNF-1
US20050171338A1 (en)	2005-08-04	Mammalian tribbles signaling pathways and methods and reagents related thereto
US6833239B1 (en)	2004-12-21	Methods to identify modulators of FKHL7 DNA-binding activity
US6399760B1 (en)	2002-06-04	RP compositions and therapeutic and diagnostic uses therefor
US20060183161A1 (en)	2006-08-17	IL-ILI gene and polypeptide products
AU6219400A (en)	2001-02-05	The il-1l1 gene and polypeptide products
WO2000047619A1 (fr)	2000-08-17	Therapeutique et diagnostics etablis sur une nouvelle mutation d'il-1b
US6518411B1 (en)	2003-02-11	RGS compositions and therapeutic and diagnostic uses therefor
US20010041353A1 (en)	2001-11-15	Novel SSP-1 compositions and therapeutic and diagnostic uses therefor
US20030022170A1 (en)	2003-01-30	Novel fibroblast growth factors and therapeutic and diagnostic uses therefor
WO1999051779A9 (fr)	2000-02-17	Traitement et diagnostic du glaucome
EP0942975A1 (fr)	1999-09-22	Proteine associee au glaucome, acide nucleique correspondant et leurs utilisations diagnostiques et therapeutiques
AU766890B2 (en)	2003-10-23	Glaucoma therapeutics and diagnostics based on a novel human transcription factor
WO1998046748A1 (fr)	1998-10-22	Compositions therapeutiques et dosages de diagnostic pour des affections liees a la trbp
US6008014A (en)	1999-12-28	Method of making lipid metabolic pathway compositions
US6271026B1 (en)	2001-08-07	Glaucoma compositions
WO1998009979A9 (fr)	1998-06-04	Compositions relatives a la voie metabolique lipidique et utilisations therapeutiques et diagnostiques de telles compositions
WO1998021363A1 (fr)	1998-05-22	Compositions et therapies utilisables contre le diabete de type ii lie au hnf-4
AU2002243454A1 (en)	2002-07-16	Mammalian tribbles signaling pathways and methods and reagents related thereto
US6306586B1 (en)	2001-10-23	Methods and compositions for the diagnosis and treatment of cataracts
AU3556402A (en)	2002-06-06	Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses

Legal Events

Date	Code	Title	Description
2003-03-27	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period